Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM1A | O60341 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18289226 | 0.90 | PIK3CD (0.51) | PIK3CDCYP2C19CYP1A2TDP1SIGMAR1 | |
| SCHEMBL25736046 | 0.82 | CARM1 (0.48) | CYP2C19TP53SMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL13282350 | 0.82 | TP53 (0.40) | PIK3CDCYP2C19SIGMAR1TP53SMN1; SMN2 | |
| SCHEMBL15160801 | 0.81 | CYP2C19 (0.47) | PIK3CDCYP2C19TP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL23323956 | 0.80 | CYP2C19 (0.42) | PIK3CDCYP2C19HRH3TP53SMN1; SMN2 | |
| SCHEMBL3314840 | 0.79 | CARM1 (0.54) | PIK3CDCYP2C19CYP1A2TDP1SIGMAR1 | |
| SCHEMBL23823660 | 0.78 | CYP1A2 (0.64) | PIK3CDCYP1A2TDP1SIGMAR1DRD3 | |
| SCHEMBL861660 | 0.78 | CYP2C19 (0.53) | PIK3CDCYP2C19CYP1A2TDP1SIGMAR1 | |
| SCHEMBL763068 | 0.77 | TP53 (0.39) | CYP2C19SIGMAR1TP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL4569283 | 0.77 | CARM1 (0.43) | SIGMAR1TP53SMN1; SMN2ALDH1A1KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239792-A1 | MODULATORS OF BCL-2 OR BCL-2/BCL-XL AND USES THEREOF | ASIA VISION LIMITED (CN) | 2024-07-18 | — | — | US | disclosed |
| US-20230321050-A1 | Heterocyclic Compounds and Uses Thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230321050-A1 | Heterocyclic Compounds and Uses Thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-11547697-B2 | Heterocyclic compounds and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| WO-2022255764-A1 | NOVEL OXAZOLE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME FOR PREVENTION OR TREATMENT OF ALLERGIC DISEASE | 주식회사 에즈큐리스 | 2022-12-08 | — | — | WO | disclosed |
| US-20190350906-A1 | Heterocyclic Compounds and Uses Thereof | INTELLIKINE, LLC | 2019-11-21 | — | — | US | disclosed |
| US-20180042902-A1 | Heterocyclic Compounds and Uses Thereof | INTELLIKINE, LLC | 2018-02-15 | — | — | US | disclosed |
| US-20180042902-A1 | Heterocyclic Compounds and Uses Thereof | INTELLIKINE, LLC | 2018-02-15 | — | — | US | disclosed |
| US-9682141-B2 | Combination of kinase inhibitors and uses thereof | INTELLIKINE LLC (US) | 2017-06-20 | — | — | US | disclosed |
| US-9682141-B2 | Combination of kinase inhibitors and uses thereof | INTELLIKINE LLC (US) | 2017-06-20 | — | — | US | disclosed |
| US-20150031672-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2015-01-29 | — | — | US | disclosed |
| US-8901133-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-20140323721-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE LLC | 2014-10-30 | — | — | US | disclosed |
| US-20140296207-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, INC. | 2014-10-02 | — | — | US | disclosed |
| US-8785454-B2 | Heterocyclic compounds and uses thereof | INTELLIKINE LLC (US) | 2014-07-22 | — | — | US | disclosed |
| US-20130261102-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2013-10-03 | — | — | US | disclosed |
| US-20130035324-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2013-02-07 | — | — | US | disclosed |
| US-20120329776-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, INC. | 2012-12-27 | — | — | US | disclosed |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE LLC (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120122838-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321050-A1 | Heterocyclic Compounds and Uses Thereof | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885CYP2C19 1191/4885CYP1A2 1496/4885 |
| US-20150031672-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885CYP2C19 1354/4885CYP1A2 2099/4885 |
| US-20240239792-A1 | MODULATORS OF BCL-2 OR BCL-2/BCL-XL AND USES THEREOF | BCL2, BCL2L2, BCL2L1 | PIK3CD 1815/4885CYP2C19 4457/4885CYP1A2 3232/4885 |
| US-20120122838-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885CYP2C19 1354/4885CYP1A2 2099/4885 |
| US-11547697-B2 | Heterocyclic compounds and uses thereof | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885CYP2C19 1191/4885CYP1A2 1496/4885 |
| US-20140323721-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885CYP2C19 1191/4885CYP1A2 1496/4885 |
| US-20130035324-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885CYP2C19 1191/4885CYP1A2 1496/4885 |
| US-20180042902-A1 | Heterocyclic Compounds and Uses Thereof | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885CYP2C19 1191/4885CYP1A2 1496/4885 |
| US-20190350906-A1 | Heterocyclic Compounds and Uses Thereof | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885CYP2C19 1191/4885CYP1A2 1496/4885 |
| US-20130261102-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885CYP2C19 1191/4885CYP1A2 1496/4885 |
| US-20140296207-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, AKT3, PIK3CD | PIK3CD 3/4885CYP2C19 1379/4885CYP1A2 2110/4885 |
| US-20120329776-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885CYP2C19 1358/4885CYP1A2 1683/4885 |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | MTOR, AKT2, MTMR1 | PIK3CD 24/4885CYP2C19 4748/4885CYP1A2 4767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.